CAS
TARS icon

Coppell Advisory Solutions’s Tarsus Pharmaceuticals TARS Stock Holding History

Coppell Advisory Solutions’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-394
Closed -$21.6K – 1681
2024
Q4 		$21.6K Sell
394
-277
-41% -$12.6K ﹤0.01% 853
2024
Q3 		$21.8K Sell
671
-11
-2% -$309 ﹤0.01% 835
2024
Q2 		$18.5K Buy
+682
New +$22.9K ﹤0.01% 818

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Coppell Advisory Solutions's TARS Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 394 shares — an estimated $21.6K sold.

Coppell Advisory Solutions first reported a position in TARS in Q2 2024 and held it in 3 quarters. The position peaked at $21.8K in Q3 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 394 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $21.6K.
  • Coppell Advisory Solutions first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Coppell Advisory Solutions's Tarsus Pharmaceuticals position peaked at $21.8K in Q3 2024.
  • 194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.